sutures newsletter

PRODUCED BY AND FOR MEMBERS OF THE DEPARTMENT OF SURGERY December 2013 | Archived Issues

Mark Your Calendar


Surgery Grand Rounds

Click the "read more" to see information about upcoming Surgery Grand Rounds.


Grand Rounds

Click here to view a schedule of all upcoming grand rounds.


Surgery Scheduling

Click the "read more" for hours and contact information for surgery scheduling.

Share Your News

Know an interesting colleague we should profile? A story we should tell? Submit your ideas, meetings and events for consideration.

Click here to submit your news to Sutures

Cedars-Sinai Patient Undergoes First-of-Its-Kind Stent Graft Procedure

A patient at Cedars-Sinai has become the first in the nation to undergo a less invasive type of stent graft procedure to repair an ascending aorta.

Ali Khoynezhad, MD, PhD

Thoracic endovascular aortic repair (TEVAR) has become the standard of care for the majority of patients with descending aortic or distal aortic arch pathologies, including aneurysms, dissections, aortic ulcers, intramural hematomas and traumatic aortic injuries. All of these pathologies are now approved indications for this less invasive procedure, according to U.S. Food and Drug Administration.

Open repair, on the other hand, remains the standard of care for all diseases of the ascending aorta, such as type A aortic dissection and aortic aneurysms.

Recently, a patient of Ali Khoynezhad, MD, PhD, director of Thoracic Aortic Surgery at Cedars-Sinai, underwent successful stent graft repair of an ascending aortic pathology. This patient is the first in the U.S. to undergo an approved stent graft procedure as part of the FDA's investigational device exemption.

Without this less invasive procedure, the patient would have needed an extensive operation involving sternotomy and open-heart surgery with a heart-lung machine to replace the ascending aorta. Instead, he had the stent graft placed though the femoral arteries and was discharged two days later.

Patients with the following conditions may be candidates for the less-invasive TEVAR as part of this FDA pathway: aortic aneurysms, type A aortic dissections, ascending aortic ulcers, and intramural hematomas and pseudoaneurysms of the ascending aorta.

If you would like to know if your patients are candidates for this less invasive procedure, contact Khoynezhad at 310-423-4345 or ali.khoynezhad@cshs.org.